1. Home
  2. REFI vs ACOG Comparison

REFI vs ACOG Comparison

Compare REFI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chicago Atlantic Real Estate Finance Inc.

REFI

Chicago Atlantic Real Estate Finance Inc.

HOLD

Current Price

$10.68

Market Cap

241.1M

Sector

Real Estate

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$9.20

Market Cap

193.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
REFI
ACOG
Founded
2021
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
241.1M
193.6M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
REFI
ACOG
Price
$10.68
$9.20
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
165.2K
148.1K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
15.79%
N/A
EPS Growth
N/A
41.58
EPS
0.57
N/A
Revenue
$48,857,628.00
$10,220,275.00
Revenue This Year
$17.47
$139.22
Revenue Next Year
$0.06
$134.48
P/E Ratio
$18.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.69
$4.50
52 Week High
$14.57
$10.14

Technical Indicators

Market Signals
Indicator
REFI
ACOG
Relative Strength Index (RSI) 59.00 63.01
Support Level $10.65 $5.28
Resistance Level $10.93 N/A
Average True Range (ATR) 0.22 0.67
MACD 0.06 0.03
Stochastic Oscillator 74.70 78.87

Price Performance

Historical Comparison
REFI
ACOG

About REFI Chicago Atlantic Real Estate Finance Inc.

Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: